Phase 3 Study to Evaluate the Efficacy and Safety of the DW0929 in Patients With Primary Hypercholesterolemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 348 participants.

Also called NCT02390375

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 348 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02390375
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02390375. Randomized; double masking; primary purpose treatment. Start 2014-11 (registry gives no type); primary completion 2016-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase 3 Study to Evaluate the Efficacy and Safety of the DW0929 in Patients With Primary Hypercholesterolemia
Condition
Hypercholesterolemia
Intervention (Drug)
DW-0929
Intervention (Drug)
DW-0929
Intervention (Drug)
DW-0929
Intervention (Drug)
Rosuvastatin
Intervention (Drug)
Rosuvastatin
Intervention (Drug)
Rosuvastatin
Lead sponsor
Daewon Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02390375
Content hash
a2cca0a7a401a6ae96bbfd54ae1e02067c86329487136397cdc62e6045c38ad9